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Abstract
Background: CGGBP1 is a CGG-triplet repeat binding protein, which affects transcription from CGG-triplet-rich
promoters such as the FMR1 gene and the ribosomal RNA gene clusters. Earlier, we reported some previously
unknown functions of CGGBP1 in gene expression during heat shock stress response. Recently we had found
CGGBP1 to be a cell cycle regulatory midbody protein required for normal cytokinetic abscission in normal human
fibroblasts, which have all the cell cycle regulatory mechanisms intact.
Results: In this study we explored the role of CGGBP1 in the cell cycle in various cancer cell lines. CGGBP1
depletion by RNA interference in tumor-derived cells caused an increase in the cell population at G0/G1 phase and
reduced the number of cells in the S phase. CGGBP1 depletion also increased the expression of cell cycle
regulatory genes CDKN1A and GAS1, associated with reductions in histone H3 lysine 9 trimethylation in their
promoters. By combining RNA interference and genetic mutations, we found that the role of CGGBP1 in cell cycle
involves multiple mechanisms, as single deficiencies of CDKN1A, GAS1 as well as TP53, INK4A or ARF failed to
rescue the G0/G1 arrest caused by CGGBP1 depletion.
Conclusions: Our results show that CGGBP1 expression is important for cell cycle progression through multiple
parallel mechanisms including the regulation of CDKN1A and GAS1 levels.
Background
CGGBP1 was identified as a CGG triplet repeat binding
protein in vitro [1]. Ever since, different studies have
focused on its ability to bind to CGG triplet repeats and
exert transcriptional repression. Previously, we found
that CGGBP1 participates in heat shock stress response
by regulating HSF1 expression through heat-sensitive
interactions with NFIX and HMGN1 [2,3]. In normal
human fibroblasts, which are expected to have all the
checkpoints and DNA repair capabilities intact, we
recently reported functions of CGGBP1 in cell cycle reg-
ulation at the abscission and consequential prevention of
tetraploidy [4]. In cancer cells however, which often
have various abnormalities in the cell cycle regulatory
mechanisms, function of CGGBP1 is unknown and is of
obvious interest since loss of cell cycle regulation is an
event central to tumorigenesis.
Cell proliferation is tightly regulated by different
mechanisms, which can halt it at an appropriate stage of
cell cycle in response to abnormalities in extracellular as
well as intracellular environment. Physical or chemical
stress to the cells, inability to respond to mitogenic sig-
nals, trans-mitotic inheritance of polyploidy, DNA
damage response or loss of function of critical cell cycle
regulatory genes [5-9] exemplify some such conditions
that can cause a cell cycle block. The kind of effects
these conditions can have on the cell cycle progression
could however vary from one cell type to the other
depending on their genetic and epigenetic profiles.
Under normal conditions, cell cycle arrest in the G0/
G1 phase is associated with the phenomena of quies-
cence, when cells do not receive enough mitogenic sti-
mulation in terms of growth factors, and senescence,
when cells are terminally differentiated and enter a
post-mitotic state [10]. Altered expression of critical
genes, due to genetic and epigenetic disturbances, can
also cause cell cycle disturbances [11-13]. The ability of
cells to undergo cell cycle arrest is paramount to the
health of any multicellular organism and a complex net-
work of proteins has evolved to execute it. The progres-
sion of cell cycle from G1 to S phase is regulated by a
well-studied series of events. The cyclin dependent
kinases CDK4 and CDK6 must interact with Cyclin D
to become active and phosphorylate Rb [14-17]. This
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phosphorylation of Rb releases it from the transcrip-
tional inhibitory complex with E2F, which then drives
the expression of many genes including Cyclin E. Cyclin
E complexes with CDK2 to drive entry into S phase.
The very first step of this cascade, interactions between
CDK4/6 and Cyclin D is inhibited by INK4A and ARF,
as they compete with Cyclin D for binding to CDK4/6
[18-20]. Another protein, CDKN1A is a multifaceted
regulator of the cell cycle. It inhibits Cyclin E-CDK2 as
well as Cyclin D-CDK4 interactions and can arrest cell
cycle at G1 or early S phase in response to DNA
damage [18-20]. Furthermore, CDKN1A expression is
controlled by TP53, a strong tumor suppressor gene
activated by DNA damage response, which frequently
exhibiting loss of function in many cancers. The muta-
tions in some or many of these cell cycle regulatory
genes such as TP53, CDKN1A, INK4A and ARF often
underlie the aberrant control of cell cycle and the ability
of cancer cells to escape the cell cycle block at G0/G1
phase in response to the stimuli, which would normally
cause a G0/G1 arrest. The growth arrest specific gene
GAS1 is known to cause G0/G1 arrest in normal as well
as transformed cells [21,22] and the mechanisms of the
regulation of its levels are less well understood.
In this study, we combined CGGBP1 knockdown by
siRNA with different genetic mutations of various cell
cycle regulatory genes to rigorously test how CGGBP1
regulates cell cycle in cancer cells. For this we have used
well-established human cancer cell lines and also gener-
ated new murine glioblastoma cell lines. We report that
in all the cell lines examined, CGGBP1 deficiency pro-
duced a cell cycle block at G0/G1 phase. Expression
analysis of candidate genes showed that CGGBP1 regu-
lates expression of CDKN1A and GAS1 genes. Mutation
of CDKN1A and siRNA-mediated depletion of GAS1
could not rescue the CGGBP1 deficiency-induced cell
cycle block at G0/G1 phase, suggesting that CGGBP1
controls cell cycle progression through the G1 phase
through multiple parallel mechanisms. Our results show
new functions for CGGBP1 in cell cycle, in regulation of
expression of CDKN1A and GAS1, and provide insights
into how CGGBP1 depletion overrides the redundancies
of checkpoint escape mechanisms present in different
cancer cells.
Results
CGGBP1 depletion by siRNA increases G0/G1 phase and
reduces S phase cell populations
We have previously established a protocol of siRNA-
mediated knockdown of CGGBP1 at both mRNA and
protein levels [3,4]. In this study, we used the same pro-
tocol of siRNA mediated knockdown of CGGBP1, as
described earlier [3,4], to deplete CGGBP1 in the
human glioma cell line U-2987 MG. Knockdown by
siRNA was efficient as immunofluorescence showed a
strong reduction in protein levels 96 h after transfection
as compared to control siRNA transfected cells (Figure
1, A and 1B). The cells were transfected at 50% conflu-
ence and after 96 h, while control siRNA transfected
cultures grew to confluence, CGGBP1 siRNA transfected
cultures did not show increase in cell density with no
visible difference in the proportion of dead cells, sug-
gesting that the CGGBP1 transfected cells underwent a
cell cycle arrest. Expression of the proliferation marker
Ki67 was also reduced in the CGGBP1 siRNA trans-
fected cells (Figure 1, A and 1B). Flow cytometric mea-
surement of DNA content per nucleus showed that in
the CGGBP1 depleted cultures the G0/G1 population
was increased while the population of S phase was
strongly decreased (Table 1 and Figure 1, C and 1D).
The depletion of CGGBP1 by using the previously
described UTR siRNA against CGGBP1 [4] also gener-
ated a similar cell cycle arrest in G1/G0 phase with a
concomitant decrease in the S phase in U-2987 MG
cells stably transfected with an empty expression vector
(Additional File 1). However, in U-2987 MG cells stably
expressing CGGBP1 from a UTR-devoid transcript, the
UTR siRNA failed to produce the G0/G1 arrest (Addi-
tional File 1), showing the specificity of siRNA response.
These results showed that in the U-2987 MG cells,
CGGBP1 is required for normal cell cycle progression
Figure 1 CGGBP1 siRNA causes decrease in CGGBP1 expression
and Ki67 positivity of the nuclei in U-2987 MG cells and blocks
cell cycle at G0/G1 phase. A: Control siRNA, B: CGGBP1 siRNA, C:
Flow cytometric pattern of U-2987 MG cells treated with control
siRNA, D: Flow cytometric pattern of U-2987 MG cells treated with
CGGBP1 siRNA. The strong decrease in the S-phase population in D
as compared to C is visible in the plots. See table 1 for details.
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and its depletion results in a cell cycle arrest character-
ized by an accumulation of cells in the G0/G1 phase
and a parallel reduction in the S-phase population.
CGGBP1 deficiency increases the expression of some key
cell cycle regulatory genes
To identify the mechanisms through which CGGBP1
depletion might cause the cell cycle arrest at G0/G1
phase, we focused on the function of CGGBP1 as a
transcription-regulatory protein. We tested the possibi-
lity if CGGBP1 could regulate expression of key genes
coding for proteins involved in cell cycle control at the
G0/G1 phase. U-2987 MG cells were transfected with
control or CGGBP1 siRNA and relative changes in
mRNA levels of a panel of candidate genes including
CDKN1A and GAS1 were assayed by quantitative real
time RT-PCR (Figure 2A). The mRNA levels of these
genes were significantly increased upon CGGBP1 siRNA
treatment in assays performed on cDNA samples from
three independent transfections. Western blot analysis
showed that CDKN1A and GAS1 protein levels were
increased upon CGGBP1 depletion (Figure 2B).
CGGBP1 is known to regulate transcription by directly
binding to CGG tandem repeats or through its associa-
tion with other transcription regulatory proteins such as
NFIX and HMGN1 [1-3]. Of all the CGGBP1 target
genes analyzed, CDKN1A had the strongest increase in
expression (Figure 2). Although CDKN1A promoter [23]
is CpG rich, it does not contain CGG repeats. However,
it contains NFI-binding site and is regulated by NFI pro-
teins including NFIX [23]. However, an in silico analysis
of promoter sequences (3 Kb upstream and downstream
regions from the transcription start site) showed the
genomic region harboring the GAS1 gene contains
Table 1 Effect of CGGBP1 depletion in different cell types on the percentage of cells in different stages of cell cycle as
measured by flow cytometric analysis of DNA content per nucleus
Cells siRNA G1/G0 (% of total) S (% of total) G2/M (% of total)
U-2987 MG Control 84.58 ± 0.16 9.95 ± 0.18 5.44 ± 0.1
CGGBP1 89.68 ± 0.28 2.85 ± 0.04 7.45 ± 0.29
U-2987 MG-vector Control 64.59 ± 0.72 26.83 ± 0.85 8.57 ± 0.36
UTR 70.03 ± 0.18 22.34 ± 0.35 7.51 ± 0.12
U-2987 MG-CGGBP1 Control 60.82 ± 2.48 28.56 ± 3.04 10.61 ± 0.71
UTR 60.52 ± 2.14 28.46 ± 3.56 11.01 ± 1.49
HCT116 p53+/+;p21+/+ Control 87.12 ± 0.39 11.39 ± 0.05 1.48 ± 0.38
CGGBP1 91.94 ± 0.64 6.88 ± 1.16 1.17 ± 0.51
HCT116 p53-/-;p21+/+ Control 87.46 ± 0.47 10.15 ± 0.44 2.38 ± 0.02
CGGBP1 91.54 ± 0.05 7.66 ± 0.03 0.8 ± 0.04
HCT116 p53+/+; p21-/- Control 88.44 ± 0.45 10.50 ± 0.39 1.05 ± 0.06
CGGBP1 92.76 ± 0.22 5.55 ± 0.24 1.67 ± 0.02
U2OS Control 49.82 ± 0.35 37.09 ± 0.45 13.08 ± 0.55
CGGBP1 68.83 ± 0.58 19.29 ± 0.25 11.86 ± 0.47
SAOS2 Control 66.34 ± 0.73 20.58 ± 0.57 12.65 ± 0.50
CGGBP1 75.65 ± 0.49 11.88 ± 0.25 12.46 ± 0.52
WT (Ink4a+/+;Arf+/+) Control 66.97 ± 0.82 29.85 ± 0.91 3.14 ± 0.12
CGGBP1 75.42 ± 0.58 20.79 ± 0.76 3.78 ± 0.19
Ink4a-/- Control 71.52 ± 0.61 27.18 ± 0.16 1.29 ± 0.64
CGGBP1 77.91 ± 0.64 17.82 ± 0.36 4.26 ± 0.32
Arf-/- Control 56.33 ± 1.07 40.13 ± 1.32 3.53 ± 0.62
CGGBP1 68.99 ± 0.78 28.80 ± 0.74 2.19 ± 0.05
U-2987 MG Control 76.04 ± 0.49 18.75 ± 5.21 5.21 ± 0.32
CGGBP1 84.88 ± 0.60 8.04 ± 7.07 7.07 ± 0.42
GAS1 72.33 ± 0.40 20.22 ± 0.20 7.44 ± 0.60
CGGBP1+ GAS1 92.44 ± 0.32 3.79 ± 0.08 3.76 ± 0.23
N = 3 independent transfections in each case. The differences between the G1/G0 phase and S phase values for control siRNA and CGGBP1 siRNA (or between
control siRNA and CGGBP1+GAS1 siRNA combined for the last sample) are significant (Heteroscedastic two tailed T test, p < 0.05). Difference between control
siRNA and UTR siRNA is significant for U-2987 MG-vector But insignificant for U-2987 MG-CGGBP1 (Heteroscedastic two tailed T test, p < 0.05). Please note that
close to 50% reductions in the S phase populations of most samples due to CGGBP1 knockdown is reflected as a rather minor yet significant increase in the G0/
G1 phase populations.
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many small interrupted CGG repeats along the entire
length of the gene, which contains only one exon and
no introns.
Since the increased expression of CDKN1A and GAS1
could be associated with cell cycle arrest in G0/G1, we
wanted to understand the mechanisms through which
CGGBP1 might regulate expression of CDKN1A and
GAS1. To this end, we assayed how CGGBP1 depletion
affects the transcription regulatory chromatin profiles at
GAS1 and CDKN1A promoters.
CGGBP1 binds to and affects chromatin profiles at the
CDKN1A and GAS1 promoters
Chromatin immunoprecipitation (ChIP) assays showed
that CGGBP1 was associated with the CDKN1A promo-
ter (Figure 3A). Histone H3K9 trimethylation, a tran-
scription repressive histone modification, was reduced at
the CDKN1A promoter in CGGBP1 depleted samples
compared to the control siRNA (Figure 3B). ChIP-quan-
titative PCRs (qPCRs) showed that CGGBP1 depletion
did not affect the level of histone H3K16 acetylation at
the CDKN1A promoter (Figure 3C).
ChIP assays for CGGBP1 binding to the flanking
regions of the GC-rich GAS1 gene showed that
CGGBP1 was recruited to this locus (Figure 3D). H3K9
trimethylation was significantly reduced by CGGBP1
depletion (Figure 3E). However CGGBP1 depletion did
not affect H3K16 acetylation in this region (Figure 3F).
These results showed that CGGBP1 maintains a speci-
fic H3K9 trimethylation code at the CDKN1A and
GAS1 promoters, which is disturbed after its depletion
and is associated with their increased expression.
The G0/G1 arrest caused by CGGBP1 siRNA does not
depend singly on TP53, CDKN1A, INK4A, ARF or GAS1
expression
We then tested if the expression of the above mentioned
cell cycle regulatory genes, is required for CGGBP1
siRNA-induced G0/G1 arrest. We performed cell cycle
Figure 2 CGGBP1 depletion in U-2987 MG cells is associated
with increased expression of CDKN1A and GAS1. A: A strong
decrease in CGGBP1 mRNA expression shows the efficiency of siRNA
transfections. Using GAPDH as control, increase in the mRNA levels
of CDKN1A and GAS1 was seen. RNA samples from duplicate
transfections were pooled and analyzed in triplicates and relative
change in expression calculated by delta delta Ct method. All
changes in expression are significant between control siRNA and
CGGBP1 siRNA treatments (p < 0.05). Values for control siRNA in
each case is normalized to 1 and not depicted. Plotted values are
average ± S.D. and significance was calculated using
heteroscedastic two-tailed T-test. B: Western blot analyses showed
that CDKN1A and GAS1 expression were increased at protein level
also. The mRNA levels of TP53 and ARF were also increased, but
their protein levels were not increased as detected by western blots
(data not shown). ACTB (top panel), CGGBP1 and GAS1 were run on
the same blot. ACTB (lowest panel) and CDKN1A were run from
same samples on a different blot.
Figure 3 CGGBP1 regulates H3K9 trimethylation levels at
CDKN1A and GAS1 promoters. A: CGGBP1 binds to CDKN1A
promoter and this is sensitive to CGGBP1 siRNA, thus showing the
specificity of the assay. B: H3K9 trimethylation is reduced at the
CDKN1A promoter after CGGBP1 depletion whereas as shown in C,
H3K16 acetylation was not significantly changed. D: CGGBP1 binds
to GAS1 promoter in a CGGBP1 siRNA-sensitive manner. E: H3K9
trimethylation in GAS1 promoter region is reduced by CGGBP1
depletion whereas the H3K16 acetylation in this region was
unaffected by CGGBP1 depletion (F). For exact region details of the
assayed region of CDKN1A and GAS1 promoters, see primers
mentioned in materials and methods. ChIP DNA samples from 3
independent assays were pooled and analyzed in triplicates. Input
DNA was used to normalize the amount of DNA and used as
baseline in double delta Ct calculations to find out relative changes
in DNA-protein interactions. Changes in real-time PCR are significant
(p < 0.05, heteroscedastic two-tailed T-test) in B and E only. For B, C,
E and F, the black bars represent the control siRNA treated samples
and the white bars represent CGGBP1 siRNA treated samples.
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analyses in cells of different genetic backgrounds trans-
fected with control or CGGBP1 siRNA. For all the
batches of siRNA transfections, CGGBP1 knockdown
was confirmed by real time qRT-PCR (not shown).
First, we asked if the increased level of CDKN1A is
the key event underlying the CGGBP1 siRNA-induced
G0/G1 arrest. We compared the effects of CGGBP1
siRNA in HCT116 human colon cancer cell lines either
WT or deficient for CDKN1A. CGGBP1 depletion in
HCT116 cells null for CDKN1A was additionally con-
firmed by western blotting at different time points (Fig-
ure 4A). CGGBP1 siRNA caused G0/G1 arrest in the
cells irrespective of the CDKN1A genotype showing that
CDKN1A is not required for CGGBP1 depletion-
induced cell cycle arrest (Table 1 and Additional Files 2
and 3). Similar assay comparing WT or TP53 null
HCT116 cells (Figure 4B) showed that even TP53 defi-
ciency alone could not rescue CGGBP1 siRNA induced
cell cycle arrest as both WT and TP53 null cells showed
a similar G0/G1 arrest (Table 1 and Additional Files 2
and 4). Transfection of control or CGGBP1 siRNA into
U2OS (TP53 WT) and SAOS2 (TP53 deficient) cells
showed that although the G0/G1 arrests were stronger
in U2OS than in SAOS2, it did occur in both the cell
lines (Table 1 and Additional Files 5 and 6). These
results suggested that TP53 and CDKN1A are not single
determinants of cell cycle regulation by CGGBP1.
We then investigated if the cell cycle inhibitors INK4A
and ARF are required for CGGBP1 depletion induced
G0/G1 arrest. Using the RCAS/TV-A system [24] we
established mouse glioma cell lines, derived from
PDGFB induced tumors, in Ntv-a (the avian TVA recep-
tor for RCAS virus driven by Nestin promoter) trans-
genic mice with wild type, Ink4A-/- or Arf-/- genetic
backgrounds. One cell line from each genotype was
tested for the effects of control or CGGBP1 siRNA on
their cell cycle patterns. A G0/G1 arrest with reductions
in S phase population was seen in all the three cell lines
(Table 1 and Additional Files 7, 8 and 9). These results
established that INK4A and ARF are not the master reg-
ulators of CGGBP1 depletion induced G0/G1 arrest.
Finally we tested if knocking down the GAS1 levels in
CGGBP1 depleted cells would rescue the CGGBP1
siRNA-induced cell cycle arrest. Equimolar amounts of
control siRNA, CGGBP1 siRNA, GAS1 siRNA or a 1:1
molar cocktail of CGGBP1 and GAS1 siRNA were
transfected into U-2987 MG cells and later analyzed by
flow cytometry. Like CGGBP1, GAS1 knockdown was
confirmed by real time qRT-PCR (not shown). As com-
pared to the control siRNA, CGGBP1 siRNA produced
a G0/G1 arrest as before (Table 1 and Additional File
10), whereas the GAS1 siRNA alone produced a mild
but insignificantly increased flux through S phase and a
decrease in the G0/G1 population was seen (Table 1
and Additional File 10). However, a combination of
GAS1 and CGGBP1 siRNA failed to rescue the G0/G1
arrest. Surprisingly, we saw a further increase in the G0/
G1 population and stronger reductions in the S- and
G2/M phases (Table 1 and Additional File 10). These
Figure 4 CGGBP1 siRNA causes CGGBP1 depletion in HCT116
cells. CGGBP1 siRNA causes CGGBP1 depletion in HCT116 cells
deficient for CDKN1A (p21) (A) or TP53 (p53) (B). Different time
points after siRNA transfections are indicated on the top of each
lane. ACTB expression was used as loading control.
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results suggested that GAS1 is not the key regulator of
CGGBP1 siRNA-induced cell cycle arrest and that the
increased efflux of cells from G0/G1 phase into the S-
phase caused by GAS1 knockdown is unsustainable in
the absence of CGGBP1.
Discussion
Regulation of cell cycle through the G1 phase transition
has been a hitherto unknown function of CGGBP1. Our
previous work has shown that CGGBP1, a transcription
regulatory protein, participates in heat shock and related
stress responses [3], is a midbody protein with AURKB-
like expression and is involved in abscission [4].
Of all the previously known functions of CGGBP1, its
role in transcription [2] has been evaluated here for the
G0/G1 arrest phenotype observed in cancer cells in this
study. Our results show that transcription regulation of
cell cycle regulatory genes is a mechanism through which
CGGBP1 might affect the cell cycle progression. While we
found increases in the transcript levels of TP53 (not
shown), CDKN1A, GAS1 and ARF (not shown) genes
after CGGBP1 depletion, we addressed the mechanism of
expression regulation only for CDKN1A and GAS1 genes
as only for these genes the changes in transcript levels
were correlated with a change in protein levels. We tested
the histone acetylation and methylation profile of the
CDKN1A and GAS1 promoters and found that H3K9 tri-
methylation, a well-established transcription repressive his-
tone modification [25,26] was reduced and this reduction
could well explain the increase in CDKN1A transcript
levels. CGGBP1 is known to require CGG triplet repeats
to bind to the DNA and execute its transcriptional regula-
tory functions. However, CDKN1A promoter in the pre-
sent study has turned out to be a CGG-repeat-free region,
which exhibits binding to CGGBP1 and undergoes
changes in H3K9 trimethylation upon CGGBP1 depletion.
This shows that CGG repeats are not absolutely required
for CGGBP1 binding and activity. H3K9 trimethylation
could induce compaction of the chromatin and recruit
chromobox domain containing proteins, which can in turn
recruit transcription repressors to the locus [25,26]. H3K9
trimethylation can also result from and lead to CpG
methylation of the DNA interestingly, the region around
the CDKN1A transcription site is GC-rich and could be
subjected to changes in CpG methylation. Similar observa-
tions about the changes in the histone modifications were
also made at the GAS1 locus, which is rich in small inter-
rupted CGG repeats. While the levels of H3K16 acetyla-
tion were unaffected, H3K9 trimethylation were decreased.
These results suggest that the control of H3K9 trimethyla-
tion is a mechanism by which CGGBP1 manifests its
effects on transcriptional regulation of different genes,
including CDKN1A and GAS1. Interestingly, CGGBP1 has
been reported to be a binding partner of SUV39H2 [27].
SUV39H2 has been shown to a member of the family of
histone methyltransferases and can control histone H3K9
trimethylation levels [28]. How CGGBP1 affects SUV39H2
binding to the DNA and affects its H3K9 tri-methylation
activity will be an interesting topic for future work.
We could address the effects of the functional defi-
ciencies of TP53, CDKN1A, GAS1, INK4A and ARF
genes on CGGBP1 siRNA-induced G0/G1 arrest by test-
ing the deficiencies of only one gene at a time, while the
increased expression of these genes occur simulta-
neously upon CGGBP1 depletion. Our results show that
none of these genes are single master regulators of the
cell cycle regulatory events downstream of CGGBP1.
Due to the complexity of the signal transduction path-
ways, it is difficult to predict if a combined functional
deficiency of these genes would rescue the effects of
CGGBP1 siRNA on cell cycle progression or not. Our
conclusions are also confounded by the fact that the
genotypes of the different cell types used in this study,
at all major cell cycle regulatory genes, is not known
and to establish them is beyond the scope of this study.
Nevertheless, using the matched background genotypes
of HCT116 cells, widely used P53 null and WT pairs of
SAOS2 and U2OS and combinations of siRNAs against
CGGBP1 and GAS1, we can safely conclude that of
TP53, CDKN1A, GAS1, INK4A and ARF, none alone is
a critical master regulator of the G0/G1 arrest induced
by CGGBP1 depletion. These results underscore the fact
that although multiple checkpoint escape mechanisms
exist in different cancer cells, ablation of CGGBP1 func-
tion compromises their ability to escape from the
mechanisms blocking cell cycle in G0/G1 phase.
CGGBP1 thus regulates cell cycle through multiple par-
allel mechanisms and further studies on its mechanisms
of action will be important in understanding how cancer
cell proliferation could be controlled.
Conclusions
CGGBP1 is required for the ability of cancer cells to
progress cell cycle beyond G0/G1 phase even if they
have single deficiencies of functional TP53, CDKN1A,
INK4A, ARF and GAS1 genes. This shows that the
absence of CGGBP1 overrides the ability of cancer cells
to escape the cell cycle block at G0/G1 phase, conferred
by lack of the above mentioned cell cycle regulatory
genes. CGGBP1 seems to regulate the passage through
G0/G1 phase through multiple parallel mechanisms.
Our results necessitate investigations into expression
and function of CGGBP1 in cancers.
Methods
Cell culture and siRNA transfections
U-2987 MG cells were previously described as the cell
line number 18 by Hagerstrand and co-workers [29]. U-
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2987 MG cells were cultured in Eagle’s minimum essen-
tial medium (SIGMA). Human CGGBP1 siRNA, UTR
siRNA and control siRNA (Dharmacon) have been
described before [3,4]. All siRNA transfections were
done using Dharmafect 2 transfection reagent. The
molarity of siRNA was equal between different samples
compared against each other for all the assays (200 nM
for the samples included in the assays involving GAS1
knockdown and 100 nM for all other assays). Mouse
CGGBP1 siRNA (catalogue number L-057812-01),
human GAS1 siRNA (catalogue number L-011665-00)
and control siRNA (catalogue number D-001810-10)
were from Dharmacon, ThermoScientific.
Immunofluorescence
Ki67 and CGGBP1 were detected by immunofluores-
cence using a mouse monoclonal anti-human Ki67
(DAKO) and a rabbit polyclonal anti-human CGGBP1
(GenTex). The cells were transfected with siRNA, 96 h
later fixed using 4% formaldehyde in 1 × PBS for 10
minutes, permeabilized using 2% Triton X-100 for 10
minutes and blocked using 10% FCS and 3% BSA in 1 ×
PBS for 1 h. Primary antibodies were mixed and diluted
in 1 × PBS with 0.2% Triton X-100 (Ki67 1:250 and
CGGBP1 1:500) and flooded on cells for 1 h at room
temperature. Cells were washed with 1 × PBS with 0.2%
Triton X-100 for 10 minutes 3 times and incubated
with a mixture of secondary antibodies (FITC-donkey
anti-rabbit from Invitrogen, 1:500 and RRX-donkey anti-
mouse from Jackson Labs, 1:400) for 1 h. Washings
were performed with 1 × PBS with 0.2% Triton X-100
for 10 minutes, 3 times and cells were mounted with a
DAPI containing aqueous mounting medium. Cells were
analyzed with a Zeiss Meta confocal microscope.
Western blot analysis
Western blot analyses were performed using 4-12% Bis-
Tris gels of NuPAGE electrophoresis system from Invi-
trogen. The gels were run using MES or MOPS buffers
(Invitrogen). Primary antibodies were as follows: ACTB
(SIGMA), CGGBP1 (ABCAM), GAS1 (GenTex),
CDKN1A (Roche). Semi-dry transfers were performed
on nitrocellulose membranes (GE Life Sciences) using
NuPAGE transfer buffer (Invitrogen). All HRP-conju-
gated secondary antibodies were from GE Life Sciences
and chemiluminescent substrate for HRP was from
Pierce.
Real time quantitative RT-PCRs (q-RTPCR)
Real time q-RTPCRs were performed using the SYBR
Green master mix from Applied Biosystems. RNA from
pooled cells from double assays was extracted from
siRNA treated cells and cDNA was made from 2 μg of
total RNA using reverse transcription reagents from
New England Biolabs in a 100 μl reaction mix. The
cDNA was diluted to 1 ml and 10 μl was used as a tem-
plate for each assay. Real time assays were run on a
Stratagene PCR machine and melting curve was used to
assure specific amplification of PCR products. Results
were analyzed using double delta Ct method. The Ct
values for GAPDH as a control for the amount of RNA
were used for first delta Ct deduction and the delta-Ct
values from control siRNA were used for the second
delta delta Ct deductions. All assays were performed in
triplicates and results plotted as average ± S.D. Signifi-
cance was calculated by performing heteroscedastic two-
tailed T-test in Excel. The primers were: CDKN1A
(ATGAAATTCACCCCCTTTCC and CCCTAGGCTG
TGCTCACTTC), TP53 (GGCCCACTTCACCGTAC-
TAA and GTGGTTTCAAGGCCAGATGT), INK4A
(ACCGGAGGAAGAAAGAGGAG and CGTAACTAT
TCGGTGCGTTG), ARF (AGTTAAGGGGGCAGGA
GTG and GGCTCCTCAGTAGCATCAGC) and GAS1
(CGGAGCTTGACTTCTTGGAC and CCCAACCCTT-
CAAATTGCTA). Primers for CGGBP1 and GAPDH
RTPCRs have been described elsewhere [3].
Cell cycle analysis by flow cytometry
For cell cycle analysis by flow cytometry, propidium
iodide staining of nuclei was performed as described
earlier [30,31]. Stained nuclei were analyzed on a BD
Biosciences flow cytometer and result files analyzed
using automatic settings in the ModFit program. Assays
were performed on three independent and parallel
transfections and the values of 2N (G0/G1 phase), 4N
(G2/M phase) and intermediate (S phase) populations
was averaged and significance calculated using hetero-
scedastic two-tailed T-test in Excel.
Chromatin immunoprecipitation assays and quantitative
PCRs
Chromatin immunoprecipitation (ChIP) assays and
quantitative PCRs on ChIP DNA were performed as
described earlier [3]. For CDKN1A ChIP assays the
chromatin was sheared to a size range of < 500 base
pairs. For GAS1 ChIP assays the chromatin was sheared
to a size range of between 500 base pairs and 1 Kb and
the PCR mixes were supplemented with DMSO to a
final concentration of 10% v/v. The changes shown in
Figure 3A, B and 3C are using the primers ACTGGGG-
GAGGAGGGAAG and GCGGCCCTGATATACAACC
in CDKN1A promoter. Using further upstream primers
(CTCTCCAATTCCCTCCTTCC and AGAAGCACCT
GGAGCACCTA), or further downstream primers (AG
CGGAGTGGAGTAAGTTCG and TCACCTCCTCGCT
AGTCCTT) the enrichment using CGGBP1 antibody
versus serum control was very low as compared to
the results shown in A (data not shown). The results
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shown in C, D and F are using the primer pair
GCGGGTTGTAAGCATCTCAT and
CATCTGTGCTTTCGACTGGA. Primers closer to the
GAS1 transcription start site did not work likely due to
the high CGG richness of the DNA in that region. All
primer sequences are from 5’end to the 3’end of the
synthesized oligonucleotides.
Generation of mouse glioma cell cultures
Mouse glioma cell cultures were established from
PDGF-B induced gliomas in Ntv-a wildtype, Ink4a-/- or
Arf-/- mice [32,33]. Mouse brain tumors were generated
by intracerebral injection of 5 μl of RCAS-PDGFB-IRES-
eGFP producing DF-1 chicken fibroblasts into newborn
mice. The injected mice were sacrificed when showing
any sign of sickness, but at the latest at 12 weeks of age.
The brains were collected under aseptic conditions and
a coronal section was made at the injection site and one
part was collected and embedded in paraffin post forma-
lin fixation or snap-frozen and embedded in OCT,
whereas the other part was minced and dissociated for
culturing. The mouse cell lines were cultured in Dulbec-
co’s Modified Eagle’s Medium (DMEM, Sigma Aldrich)
supplemented with 10% fetal bovine serum (FBS,
Gibco), 4 mM L-glutamine and 100 units/ml penicillin
and 0.1 mg/ml streptomycin (Sigma Aldrich). All cells
were grown at 37°C with 5% CO2. All animal experi-
ments were approved by the “Ethical Committee for
Animal Experiments in Uppsala (Sweden)”. The ethical
approval number for these animal experimentations
from the Swedish Agriculture Board was C18/6.
Additional material
Additional file 1: Flow cytometric pattern of U-2987 MG cells stably
selected for containing an empty vector (PCDNA3.1+) or CGGBP1-
expressing vector, transfected with control or UTR siRNA. The
CGGBP1 UTR siRNA-induced decrease in S phase and an increase in the
G1/G0 phase cell population in U-2987 MG cells is rescued by the
expression of a UTR-free CGGBP1 cDNA and not by the empty vector
alone. This proves the specificity of the effect of the siRNA.
Additional file 2: Flow cytometric pattern of HCT116 (p21 wt and
p53 wt) cells treated with control or CGGBP1 siRNA. CGGBP1 siRNA
produces a decrease in S phase and an increase in the G1/G0 phase cell
population in HCT116 cells with wild-type p21 and p53 genes.
Additional file 3: Flow cytometric pattern of HCT116 (p21 null) cells
treated with control or CGGBP1 siRNA. CGGBP1 siRNA produces a
decrease in S phase and an increase in the G1/G0 phase cell population
in HCT116 cells with mutant p21 and wild-type p53 genes.
Additional file 4: Flow cytometric pattern of HCT116 (p53 null) cells
treated with control or CGGBP1 siRNA. CGGBP1 siRNA produces a
decrease in S phase and an increase in the G1/G0 phase cell population
in HCT116 cells with wild-type p21 and mutant p53 genes.
Additional file 5: Flow cytometric pattern of SAOS2 cells treated
with control or CGGBP1 siRNA. CGGBP1 siRNA produces a decrease in
S phase and an increase in the G1/G0 phase cell population in SAOS2
cells. These cells are known to be p53 deficient.
Additional file 6: Flow cytometric pattern of U2OS cells treated with
control or CGGBP1 siRNA. CGGBP1 siRNA produces a decrease in S
phase and an increase in the G1/G0 phase cell population in U2OS cells.
These cells are known to have wild-type p53.
Additional file 7: Flow cytometric pattern of mouse glioblastoma
cells (INK4A WT and ARF WT) treated with control or CGGBP1
siRNA. Mouse CGGBP1 siRNA produces a decrease in S phase and an
increase in the G1/G0 phase cell population in PDGFB-overexpressing
mouse glioma cell lines which are wild-type for INK4A and ARF.
Additional file 8: Flow cytometric pattern of mouse glioblastoma
cells (INK4A-/-) treated with control or CGGBP1 siRNA. Mouse
CGGBP1 siRNA produces a decrease in S phase and an increase in the
G1/G0 phase cell population in PDGFB-overexpressing mouse glioma cell
lines which are mutant for INK4A and wild-type for ARF.
Additional file 9: Flow cytometric pattern of mouse glioblastoma
cells (ARF-/-) treated with control or CGGBP1 siRNA. Mouse CGGBP1
siRNA produces a decrease in S phase and an increase in the G1/G0
phase cell population in PDGFB-overexpressing mouse glioma cell lines
which are mutant for INK4A and wild-type for ARF.
Additional file 10: Flow cytometric pattern of U-2987 MG cells
treated with control, CGGBP1, GAS1 or CGGBP1+GAS1 siRNA. While
the CGGBP1 siRNA produces a decrease in S phase and an increase in
the G1/G0 phase cell population in U-2987 MG cells, GAS1 siRNA caused
increased proliferation, represented by an increased flux of cells into the
S phase. Combination of CGGBP1 and GAS1 siRNA showed that in the
absence of CGGBP1, the increased S-phase population of cells caused by
GAS1 depletion is unsustainable. The combination of the two siRNA thus
caused a synergistic and stronger G1/G0 arrest and decrease in the S
phase population.
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